US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

ALLO Allogene Therapeutics Inc

2.49

0.03 (1.22%)

31 May 2024 - Cerrado

Retrasado por 15 minutos

Form 3 - Initial statement of beneficial ownership of securities

Allogene Therapeutics (NASDAQ:ALLO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Haga Click aquí para más Gráficas Allogene Therapeutics.

Allogene Therapeutics (NASDAQ:ALLO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024

Haga Click aquí para más Gráficas Allogene Therapeutics.

Noticias sobre Allogene Therapeutics Inc ALLO

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Jueves 23 de Mayo 2024 (1 semana hace) • GlobeNewswire Inc.

Form 8-K - Current report
Martes 14 de Mayo 2024 (3 semanas hace) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Martes 14 de Mayo 2024 (3 semanas hace) • Edgar (US Regulatory)

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Lunes 13 de Mayo 2024 (3 semanas hace) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Lunes 13 de Mayo 2024 (3 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Lunes 13 de Mayo 2024 (3 semanas hace) • Edgar (US Regulatory)

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
Lunes 13 de Mayo 2024 (3 semanas hace) • GlobeNewswire Inc.

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Lunes 6 de Mayo 2024 (4 semanas hace) • GlobeNewswire Inc.

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Viernes 26 de Abril 2024 (1 mes hace) • GlobeNewswire Inc.

Allogene Therapeutics Announces Q2 Investor Conference Participation
Martes 9 de Abril 2024 (2 meses hace) • GlobeNewswire Inc.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Jueves 14 de Marzo 2024 (3 meses hace) • GlobeNewswire Inc.

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Martes 12 de Marzo 2024 (3 meses hace) • GlobeNewswire Inc.

Más de Allogene Therapeutics Inc Artículos de Noticias

Hsbc Usa Inc Issuer Call...

Expro Group Holdings NV

NLBNPIT1YC59 20351221 14...

Fidelity Advisor Sustain...

NLBNPIT1YXL0 20991231 18...

NLBNPIT1UIH7 20991231 22...

Ashland Services BV

NLBNPIT1S2M2 20241220 350

NLBNPIT20OG9 20240621 33...

Logicor Financing Sarl

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones